OTC · EMMA
Emmaus Life Sciences, Inc.
$0.04-$0.00 (-12.0%)
Emmaus Life Sciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.95% below the high.
Loading market information…
OTC · VPRO · USD
Stock price
Quote as of Oct 28, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Viropro Inc.’s quoted price sits in the lower half of its reported 52-week range, 80.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
Viropro Inc., a subsidiary of Alpha Biologics Limited, functions as a contract research and manufacturing organization (CRMO), primarily engaged in the development and production of biotherapeutic proteins aimed at treating diverse medical conditions. The company additionally facilitates the industrial-scale manufacturing of biogeneric therapeutic proteins through the licensing of its proprietary technologies, targeting illnesses like cancer, diabetes, hepatitis, and multiple sclerosis. Viropro manufactures a range of biologics drugs, including biosimilars, for use across all phases of clinical development, from pre-clinical studies through Phase I, II, and III trials. Its offerings to clients include the provision of mammalian cell proteins, such as monoclonal antibodies, recombinant proteins, and other cell-derived compounds. Notably, the firm owns three proprietary clones: two intended for insulin-related therapies and one for cancer treatment. Viropro delivers extensive contractual research and manufacturing solutions to biotech and biopharmaceutical enterprises, performing tasks such as cloning, sequencing, purification, development, validation, and production of biopharmaceutical components and finished products. The company maintains operational presences in Canada, the United Kingdom, and Malaysia, and has established a partnership with Oncobiologics, Inc. for the creation and commercialization of monoclonal antibody products. Viropro Inc. is headquartered in San Jose, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.04-$0.00 (-12.0%)
Emmaus Life Sciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.95% below the high.
A$0.00+A$0.00 (0.0%)
Biotron Limited’s quoted price sits in the lower half of its reported 52-week range, 60.0% below the high.
$0.01$0.00 (0.0%)
JRSIS Health Care Corporation’s quoted price sits in the lower half of its reported 52-week range, 93.5% below the high.
$0.02$0.00 (0.0%)
SQZ Biotechnologies Company’s quoted price sits in the lower half of its reported 52-week range, 65.71% below the high.
$0.00$0.00 (0.0%)
Café Serendipity Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 41.94% below the high.
$0.06$0.00 (0.0%)
SYBLEU Inc’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
$0.00$0.00 (0.0%)
Therapeutic Solutions International, Inc.: Healthcare · Biotechnology.
$0.00$0.00 (0.0%)
MultiCell Technologies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.0% below the high.
